NEW YORK (GenomeWeb) – Nuclea Biotechnologies said today that it is partnering with the Institut de recherches cliniques de Montréal (IRCM) to validate mass spec assays for insulin, proinsulin, and c-peptide.
Under the partnership the two companies will run the assays on clinical sample cohorts at both Nuclea and IRCM's facilities to test the precision, sensitivity, and reproducibility of the assays.